| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697505 | Cancer Treatment and Research Communications | 2017 | 4 Pages |
Abstract
New treatment agents have not shown sufficient efficacy against advanced squamous cell lung cancer. In the present phase II study, the primary endpoint was the objective response rate, and the combination of nedaplatin and paclitaxel appeared safe and effective for untreated advanced squamous cell lung cancer. The objective response rate was 72.2%, and the disease control rate was 100%.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Takashi Kasai, Takayuki Kaburagi, Tomohide Sugiyama, Yutaka Yamada, Yoichi Nakamura, Yukari Kamiyama, Kiyoshi Mori,